Screen the entire global market — including names the crowd has left for dead — by quality, growth, returns and valuation.
Every subsector ranked on valuation, income, returns and leverage, computed from our own company financials with a book-value NAV proxy. Click a subsector for its full report.
The financials and ratios on this page come straight from the filings and are live. The judgement — what it is worth, and what would break it — is what we add.
A fast read of the filings to help decide whether this is worth a closer look. Thin by design.
See plansA full research report on the company and everything around it — the filings, the competitors, the news, the industry, the economy and the regulatory backdrop — with a full valuation model, fair value, and bear, base and bull case scenarios.
Buy the deep research · $99Put a question to the analyst and get an answer grounded in this company's own filings and our research — "what breaks the thesis?", "how much of profit goes to interest?"
Included from Premium →It takes up to 3 hours and covers the filings, the competitors, the news, the wider industry, the economy it sits in, the regulatory backdrop, and a full model and a fair value with sensitivities. It runs in the background — we will let you know when it lands, so you do not need to keep this page open.
Annual financial statements as reported, going back as far as the data allows.
| $m | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E |
|---|
| $m | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E |
|---|
| $m | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E |
|---|
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E |
|---|
Who bought and sold, at what price, and how much of their own holding it was — from SEC Form 4, UK PDMR and EEA MAR Article 19 notifications, with each insider's last-reported position and disclosed major holders.
A full deep-dive (business, moat, risks, valuation and scenarios) hasn't been generated for this company yet.
Source documents straight from the database — click to read the raw filing or release — beside the issuer's own releases and dated events, newest first. Our read on what matters lives in Recent developments.
Upcoming and recent investor events — results, AGM, dividend and ex-dividend dates — from the company's own investor calendar.
Every place this issuer trades — the home listing, foreign cross-listings and depositary receipts (ADR/CDR/BDR), plus any separate share classes. The screener shows one canonical line per company; the rest live here.
| Listing | Exchange | Ticker | Currency | Price | Type |
|---|
Interactive price chart with the common technical-analysis overlays and indicators — moving averages, Bollinger Bands, volume, RSI and MACD — plus an at-a-glance momentum summary. Use the chart's own toolbar to add or remove studies, change timeframe, or search a different listing.
A note on method: PrimerIQ's research is built bottom-up from the filings — what a business earns and what it's worth. The charts below read price history, not the business; we include them because many investors want them, not because they drive our valuation. Treat them as one lens among several.
Relative strength percentile: 70 vs market, 68 vs industry. Momentum rank is a 0–100 percentile across 39,530 companies — one lens, not a valuation signal.
Charts and technical data by TradingView. Not investment advice.
The webcast audio itself, transcribed in full, with the structural signals the transcript text alone loses — how scripted rather than spontaneous the language is, where management hesitated longest, and which answers were most hedged.
Included from Premium →Select a filing on the left to read it here.
Select a filing to view its raw text.